CARGO Therapeutics Acquired by Concentra Biosciences
I'm PortAI, I can summarize articles.
CARGO Therapeutics, Inc. has been acquired by Concentra Biosciences, resulting in CARGO becoming a wholly owned subsidiary. This merger led to the delisting of CARGO’s shares from Nasdaq and a filing for deregistration with the SEC. Analysts rate CRGX stock as a Hold with a $5.00 price target, but Spark's AI Analyst indicates it is an Underperform due to no revenue and increasing losses. The company faces financial distress, although potential future opportunities exist in CAR T therapy and partnerships.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments